ATE461932T1 - Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors - Google Patents

Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Info

Publication number
ATE461932T1
ATE461932T1 AT05737774T AT05737774T ATE461932T1 AT E461932 T1 ATE461932 T1 AT E461932T1 AT 05737774 T AT05737774 T AT 05737774T AT 05737774 T AT05737774 T AT 05737774T AT E461932 T1 ATE461932 T1 AT E461932T1
Authority
AT
Austria
Prior art keywords
cupyrimidines
adenosine
antagonists
receptor
Prior art date
Application number
AT05737774T
Other languages
English (en)
Inventor
Bernard Neustadt
Jinsong Hao
Hong Liu
Craig Boyle
Samuel Chackalamannil
Unmesh Shah
Andrew Stamford
Joel Harris
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461932(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE461932T1 publication Critical patent/ATE461932T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05737774T 2004-04-21 2005-04-19 Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors ATE461932T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56391304P 2004-04-21 2004-04-21
US60996604P 2004-09-15 2004-09-15
PCT/US2005/013454 WO2005103055A1 (en) 2004-04-21 2005-04-19 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE461932T1 true ATE461932T1 (de) 2010-04-15

Family

ID=34966464

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05737774T ATE461932T1 (de) 2004-04-21 2005-04-19 Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Country Status (16)

Country Link
US (1) US7709492B2 (de)
EP (1) EP1745047B1 (de)
JP (2) JP2007533754A (de)
KR (1) KR20060135901A (de)
AR (1) AR048617A1 (de)
AT (1) ATE461932T1 (de)
AU (1) AU2005236059B2 (de)
CA (1) CA2563635A1 (de)
DE (1) DE602005020127D1 (de)
ES (1) ES2342082T3 (de)
IL (1) IL178674A0 (de)
MX (1) MXPA06012231A (de)
NZ (1) NZ550591A (de)
PE (1) PE20060185A1 (de)
TW (1) TW200538118A (de)
WO (1) WO2005103055A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1283839T1 (de) * 2000-05-26 2005-08-31 Schering Corp
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP2100877B1 (de) 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyessigsäuren und Analoga
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US20080119477A1 (en) * 2004-12-13 2008-05-22 Smith Brian M N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2622741A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US7691869B2 (en) * 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
AU2009222047A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
WO2010068756A2 (en) 2008-12-10 2010-06-17 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1, 3 oxathiolanes
EP2379556A1 (de) * 2008-12-30 2011-10-26 ArQule, Inc. Substituierte 1h-pyrazolo[3,4-d]pyrimidin-6-aminver?bindungen
US8431699B2 (en) * 2009-02-27 2013-04-30 Vertichem Corporation Method for manufacture of 2-oxoimidazolidines
WO2010104194A1 (en) * 2009-03-10 2010-09-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
WO2010114894A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
BR112012007635B1 (pt) * 2009-10-08 2019-07-09 Sanofi Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
KR101795562B1 (ko) * 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
CN115873022A (zh) * 2017-03-30 2023-03-31 伊忒欧斯比利时股份公司 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
WO2018178338A1 (en) * 2017-03-30 2018-10-04 Iteos Therapeutics 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN108218796A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 含酰肼结构的化合物、制备方法及其用途
CN107935953A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含末端烯键和酰肼结构的comt抑制剂、制备方法及其用途
CN108191775A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种末端烯丙基丙酰肼结构化合物及其用途
CN108148004A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 一种含丙酰肼和嘧啶结构的化合物、制备方法及其用途
JP2021520392A (ja) 2018-04-08 2021-08-19 ベイジーン リミテッド Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026758B1 (fr) * 2018-09-11 2020-06-09 Iteos Therapeutics S A Composition pharmaceutique comprenant des dérivés de thiocarbamate inhibiteurs d’a2a
MX2021002865A (es) * 2018-09-11 2021-07-16 iTeos Belgium SA Derivados de tiocarbamato como inhibidores de a2a, composición farmacéutica de los mismos y combinaciones con agentes antineoplásicos.
BE1026615B1 (fr) * 2018-09-27 2020-07-06 Iteos Therapeutics S A Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux
BE1026602B1 (fr) * 2018-09-27 2020-06-18 Iteos Therapeutics S A Inhibiteurs d’a2a ne penetrant pas dans le cerveau et methodes d’utilisation dans le traitement de cancers
US11427594B2 (en) 2018-09-27 2022-08-30 iTeos Belgium SA Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
CN114667287A (zh) * 2019-07-17 2022-06-24 泰昂治疗公司 腺苷a2a受体拮抗剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
SI1283839T1 (de) * 2000-05-26 2005-08-31 Schering Corp
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
AR037243A1 (es) * 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
AU2003304527B2 (en) 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
EP1622912B1 (de) 2003-04-23 2009-05-27 Schering Corporation 2-alkinyl- und 2-alkenyl-pyrazolo-[4,3-e] -1,2,4-triazolo-[1,5-c] -pyrimidinadenosin a2a rezeptorantagonisten

Also Published As

Publication number Publication date
IL178674A0 (en) 2007-02-11
JP2008231111A (ja) 2008-10-02
MXPA06012231A (es) 2006-12-15
JP2007533754A (ja) 2007-11-22
TW200538118A (en) 2005-12-01
PE20060185A1 (es) 2006-03-20
DE602005020127D1 (de) 2010-05-06
AU2005236059B2 (en) 2009-01-15
ES2342082T3 (es) 2010-07-01
HK1095818A1 (en) 2007-05-18
AU2005236059A1 (en) 2005-11-03
NZ550591A (en) 2010-10-29
CA2563635A1 (en) 2005-11-03
US20050239795A1 (en) 2005-10-27
KR20060135901A (ko) 2006-12-29
AR048617A1 (es) 2006-05-10
WO2005103055A1 (en) 2005-11-03
EP1745047A1 (de) 2007-01-24
US7709492B2 (en) 2010-05-04
EP1745047B1 (de) 2010-03-24

Similar Documents

Publication Publication Date Title
DE602005020127D1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
NL1032713A1 (nl) Histamine-3-receptorantagonisten.
ATE481404T1 (de) Adenosinderivate als agonisten am a2a-rezeptor
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
ATE317844T1 (de) Adenosine a2a receptor antagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
IL186188A0 (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EP1871752A4 (de) Antagonisten des amidopropoxyphenylorexinrezeptors
DE602006003628D1 (de) Purinderivate als a2a-rezeptoragonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DE60333866D1 (de) 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
DE60305026D1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties